Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remifentanil + thiopental
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of remifentanil, an ultra-short-acting synthetic μ-opioid receptor agonist, and thiopental, a barbiturate used for anesthesia induction. This combination provides synergistic effects for anesthesia, offering stable hemodynamic responses and excellent conditions for procedures like laryngeal mask airway insertion and tracheal intubation without muscle relaxants. Recent research suggests it may also have cardioprotective effects in certain conditions.
02
Targets
GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on remifentanil + thiopental.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remifentanil + thiopental.